Premium
5‐Fluorouracil, doxorubicin, and cisplatin regimen in adrenal cortical carcinoma
Author(s) -
Schlumberger Martin,
Ostronoff Mauricio,
Bellaiche Marc,
Rougier Philippe,
Droz JeanPierre,
Parmentier Claude
Publication year - 1988
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19880415)61:8<1492::aid-cncr2820610803>3.0.co;2-1
Subject(s) - medicine , mitotane , regimen , doxorubicin , fluorouracil , cardiotoxicity , cisplatin , chemotherapy , carcinoma , adrenocortical carcinoma , oncology , metastatic carcinoma , surgery
Five patients with metastatic adrenal cortical carcinoma were treated with a combination of 5‐fluorouracil (5‐FU), doxorubicin, and cisplatin. All patients had a nonhormone producing tumor. A large tumor burden made them unsuitable for mitotane treatment. Treatment could be evaluated in four patients. A complete remission was achieved in one patient and lasted for 38 months: this patient is still alive and free of disease. Furthermore, a minor response and a disease stabilization also were observed. Cardiotoxicity occurred in one patient and myelosuppression in another patient. This regimen appears to be an active combination for the treatment of metastatic adrenal cortical carcinoma.